Biomarkers: New biomarker for Sjögren's syndrome-time to treat patients

Nature Reviews Rheumatology

Volumn 9, Issue 10, 2013, Pages 570-572

  Kroese, Frans G M ^a   Bootsma, Hendrika ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; BELIMUMAB; BIOLOGICAL MARKER; CD20 ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERFERON; LA ANTIBODY; MYXOVIRUS RESISTANCE PROTEIN A; RHEUMATOID FACTOR; RITUXIMAB; RO ANTIBODY; TOLL LIKE RECEPTOR;

DENDRITIC CELL; DISEASE ACTIVITY; HUMAN; IMMUNOPATHOGENESIS; NOTE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE I; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

EID: 84885313004     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.143     Document Type: Note

References (10)

1. Ramos-Casals, M., Brito-Zeron, P., Siso-Almirall, A., Bosch, X. & Tzioufas, A. G. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat. Rev. Rheumatol. 8, 399-411 (2012).
2. Maria, N. I. et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjögren's syndrome. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2012-202552.
3. Seror, R. et al. EULAR Sjögren's syndrome patient reported index (ESSPRI): Development of a consensus patient index for primary Sjögren's syndrome. Ann. Rheum. Dis. 70, 968-972 (2011).
4. Seror, R. et al. EULAR Sjögren's syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann. Rheum. Dis. 69, 1103-1109 (2010).
5. Moerman, R. V. et al. EULAR Sjögren's syndrome disease activity index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann. Rheum. Dis. http://dx.doi.org/10.1136/ annrheumdis-2013-203736.
6. Pollard, R. P. et al. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjögren's syndrome. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-203447.
7. Ronnblom, L. & Eloranta, M. L. The interferon signature in autoimmune diseases. Curr. Opin. Rheumatol. 25, 248-253 (2013).
8. Gottenberg, J. E. et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc. Natl Acad. Sci. USA 103, 2770-2775 (2006).
9. Hjelmervik, T. O., Petersen, K., Jonassen, I., Jonsson, R. & Bolstad, A. I. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum. 52, 1534-1144 (2005).
10. Raterman, H. G. et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res. Ther. 14, R95 (2012).